300142 沃森生物
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,141,346-32.19%4,113,7725,086,4453,462,8312,939,021
减:营业总成本1,756,031-24.34%3,152,2133,806,2232,627,6381,912,676
    其中:营业成本440,624-2.36%597,556609,469394,339399,810
               财务费用(30,050)-43.50%(70,993)(62,981)(38,721)(30,698)
               资产减值损失(98,211)681.19%(162,640)(61,466)(11,845)(4,919)
公允价值变动收益(93,690)39.03%(234,750)(199,335)(280,737)279,890
投资收益4,897-22.20%7,11411,79757,8765,400
    其中:对联营企业和合营企业的投资收益75-117.09%382(1,074)(932)181
营业利润286,083-63.29%613,9661,099,440710,2751,376,282
利润总额373,789-51.72%598,9761,070,465708,9451,373,304
减:所得税费用23,148-69.93%87,651132,239107,593162,117
净利润350,641-49.71%511,325938,226601,3521,211,187
减:非控股权益94,282-34.46%91,935209,574173,604208,000
股东净利润256,359-53.67%419,390728,652427,7481,003,187

市场价值指针
每股收益 (元) *0.160-53.64%0.2620.4550.2730.652
每股派息 (元) *----0.0100.0100.0270.070
每股净资产 (元) *5.9960.90%5.8175.6525.2984.233
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容